Blis Technologies Limited · NZX:BLT
Blis Technologies — Shareholder Meeting (August 2026)
28 slides from Blis Technologies's shareholder meeting presentation, August 2026
Slide 1: Annual Shareholder Meeting 2026
ANNUAL SHAREHOLDER MEETING 2026
Slide 2: Attendees Question & Voting Process
ATTENDEES QUESTION & VOTING PROCESS
Slide 3: Meeting Agenda
MEETING AGENDA B US INE SS OF T HE ME E TING CHAIR'S ADDRESS Dame Alison Stewart CHIEF EXECUTIVE OFFICER'S ADDRESS Scott Johnson RESOLUTIONS 1. That Paul Munro be elected as a Director 2. That pursuant to NZX Listing Rule 2.11.1, the maximum aggregate amount of remuneration payable by the Company to
Slide 4: Board of Directors
BOARD OF DIRECTORS DAME ALISON STEWART AMELIA (AIMEE) DR BARRY PAUL MUNRO ANITA JOHANSEN MCCAMMON RICHARDSON Chair, Independent Non- Independent Non- Non-executive Director executive Director Independent Non- Independent Non- executive Director executive Director executive Director Member of People
Slide 5: FY26 Summary
FY26 SUMMARY $ $ $ $ 14.7M 1.8M 1.6M 8.5M REVEN UE UN DER LYIN G EBITDA* UN DER LYIN G NPA T* CA SH & DEPOSITS ▲ 16% on prior year ▲ 83% on prior year ▲ 90% on prior year At 31 March 2026
Slide 6: CEO Address
CEO ADDRESS SCOTT JOHNSON Chief Executive Officer
Slide 7: Executive Team
EXECUTIVE TEAM SCOTT JOHNSON Chief Executive Officer (CEO) RICHARD WINGHAM Chief Financial Officer (CFO) JENNIFER WALKER Chief Revenue Officer (CRO) DR JOHN HALE Chief Technology Officer (CTO) ASHLEIGH CHILDS Head of People, Culture & PMO MELISSA DRYSDALE Head of Quality
Slide 8: Global Market Snapshot
GLOBAL MARKET SNAPSHOT PROBIOTIC DIETARY SUPPLEMENT MARKET GLOBAL PROBIOTIC DIETARY SUPPLEMENTS MARKET BY REGION (2024) Market size in USD Billion · CAGR 11.74% $24.35B 22% Europe 25% North America $12.52B $13.98B 37.8% Asia-Pacific 5.4% Rest of World 10% Middle East & Africa 2025 2026 2031 Source:
Slide 9: FY26 Financial Performance
FY26 FINANCIAL PERFORMANCE REVENUE UNDERLYING EBITDA* UNDERLYING NPAT* ▲ 16% on prior year ▲ 83% on prior year ▲ 90% on prior year 1.6 14.7 1.8 $m $m $m 12.6 11.5 0.8 1.0 0.8 0.6 FY24 FY25 FY26 FY24 FY25 FY26 FY24 FY25 FY26 * Underlying EBITDA and NPAT adjust for a $0.9m one-off supply chain cost in
Slide 10: FY26 Summary
FY26 SUMMARY CASH GENERATED FROM REVENUE BY REGION OPERATIONS FY25 FY26 ▼ 133% on prior year $m 20 Publications relating to our strains 1.8 EMEA New Zealand 1.1 17 Conferences attended or presented at Asia Pacific (excl. NZ) North America (0.6) 2 New patents granted REVENUE BY CHANNEL FY25 FY26 Prog
Slide 11: Revenue & Market Performance - B2B
REVENUE & MARKET PERFORMANCE - B2B B2B REVENUE (NZ$M) 9.9 8.0 8.1 9.9M $ B2B REVENUE ▲ 22% • Ingredient $7.3m, up 17% - the primary FY24 FY25 FY26 growth driver. • Asia Pacific up $0.9m - new South FY26 B2B REVENUE BY SALES CHANNEL Korea customer • Royalty $1.3m, up 17% Ingredient • Private label $1
Slide 12: Revenue & Market Performance - B2C
REVENUE & MARKET PERFORMANCE - B2C $ B2C REVENUE (NZ$M) 4.8M 4.8 4.5 3.5 B2C REVENUE • New Zealand Wholesale – up 20% - strong product ranging and growing focus on dental FY24 FY25 FY26 • Amazon US up 5%, despite tariffs • BLIS Webstore up 12% FY26 B2C REVENUE BY CHANNEL • CBEC $0.3m, down from $0.6
Slide 13: Intellectual Property & Market Risks
INTELLECTUAL PROPERTY & MARKET RISKS IP MATTER RESOLVED NEW PATENTS GRANTED • Patent issue with Bluestone Pharma (BSP) & Lactosan • Antiviral applications of Streptococcus salivarius K12 and M18 GmbH resolved in July 2025 • Relevant patents now jointly owned by BLIS & BSP; all claims • Enhanced form
Slide 14: Strategic Focus & Execution
STRATEGIC FOCUS & EXECUTION CONTINUED FOCUS ON EXPANDED PROBI CHINA CLINICAL TRIAL CONSUMER-INSIGHT- CORE: BLIS K12 & AGREEMENT — USA, UNDERWAY — DRIVEN R&D, NPD AND BLIS M18 CANADA, EMEA & PET COMPLETION EXPECTED BRAND REFRESH NUTRITION 1H27
Slide 15: FY27 Strategic Plan
FY27 STRATEGIC PLAN O UR P UR PO S E Being the best at developing probiotic solutions for the health and wellbeing of global consumers PEOPLE PROFIT CUSTOMER OUR IMPACT OUR VISION We are recognised globally as the preferred partner and leader in oral probiotic innovation CREATE TECHNOLOGY BLOCKS GRO
Slide 16: ESG & Culture
ESG & CULTURE B CORP CERTIFICATION MYGREEN LAB CERTIFICATION 'LEADING AT BLIS' LEADERSHIP 0 MAINTAINED PROGRAMME LTI’S - 7 YEARS LTI FREE HEALTH & SAFETY EXTERNAL AUDIT COMPLETED
Slide 17: Supply Chain
SUPPLY CHAIN ONE-OFF COST OF $0.9M IMPACTED FY26 EARNINGS ADDITIONAL FERMENTATION PARTNER
Slide 18: Closing & Outlook
CLOSING & OUTLOOK UNAUDITED RESULTS FOR THE QUARTER ENDED FY27 OUTLOOK 30 JUNE 2026 (1Q27) • FY27 full year revenue growth of 10-15% $5.1M $1.1M FY27 PRIORITIES REVEN UE EBIT DA • Accelerate growth in key markets with the right partners • Advance R&D, new product development and IP protection • Inve
Slide 19: Questions
QUESTIONS WAIT F OR THE MICROPHONE
Slide 20: Attendees Question Process
ATTENDEES QUESTION PROCESS QUESTION BOX ? Select "Ask a Question" in the online portal, type your question, and submit it to the Chair.
Slide 21: Resolutions
RESOLUTIONS WAIT F OR THE MICROPHONE
Slide 22: Attendees Voting Process
ATTENDEES VOTING PROCESS + VOTING CARD Select "Get a Voting Card" in the online portal, then cast your vote For, Against or Abstain on each resolution.
Slide 23: That Paul Munro be elected as a Director of the Company
RESOLUT ION 1 THAT PAUL MUNRO BE ELECTED AS A DIRECTOR OF THE COMPANY W A I T F O R T H E MI C R O P H O N E State your name and whether you are a shareholder or proxy holder
Slide 24: Resolution: Increase in Directors' Remuneration Pool
RESOLUT ION 2 THAT PURSUANT TO NZX LISTING RULE 2.11.1, THE MAXIMUM AGGREGATE AMOUNT OF REMUNERATION PAYABLE BY THE COMPANY TO DIRECTORS BE INCREASED FROM $309,000 PER ANNUM TO $340,000 PER ANNUM W A I T F O R T H E MI C R O P H O N E State your name and whether you are a shareholder or proxy holder
Slide 25: Resolution: Authorise Directors to Fix Auditors' Remuneration
RESOLUT ION 3 THAT THE DIRECTORS BE AUTHORISED TO FIX THE REMUNERATION OF THE AUDITORS FOR THE ENSUING YEAR W A I T F O R T H E MI C R O P H O N E State your name and whether you are a shareholder or proxy holder
Slide 26: General Business
: BLIS GENERAL BUSINESS
Slide 27: Disclaimer
DISCLAIMER I NF OR MATI ON FUT URE P ER FOR MAN CE The information in this presentation is an overview and does not contain all This presentation may contain certain ‘forward-looking statements’, for example information necessary to make an investment decision. It is intended to constitute a stateme
Slide 28: Thank You
THANK YOU PROBIOTICS MADE TO MATTER
BLIS Technologies — Shareholder Meeting (August 2026) on 6ix